The rising popularity in GLP-1 agonists for diabetes has sparked a debate about delivery methods : patches versus tablets . Usually , GLP-1 treatments were solely available in pill form, but the development of transdermal delivery provides a new choice . Transdermal systems might benefit individuals experiencing issues taking pills , those seeking